GSK (GSK) Withdraws Application for Autism Drug After Review

GlaxoSmithKline (GSK) has officially withdrawn its application for a drug associated with autism treatment that had previously garnered attention from former President Trump. The decision was made following a review process, although specific reasons or metrics regarding the review's findings were not disclosed. This move may impact GSK's reputation and future drug development in the autism domain, potentially affecting investor confidence. As of now, the trading implications remain uncertain due to the lack of detailed financial data surrounding the application.